Page |1 |of |31
NAMS CERTIFICATION EXAM NEWEST 2026 ACTUAL
EXAM QUESTIONS AND CORRECT DETAILED
ANSWERS (VERIFIED ANSWERS) ALL ANSWERED
{115 Q & A} ALREADY GRADED A+ (BRAND NEW!)
BRCA 1/2 Surgical Considerations
| | |
Bilateral-risk reducing breast surgery and BSO can decrease risks
| | | | | | | |
of cancer
| |
Secondary Amenorrhea differential with low FSH
| | | | |
- Pregnancy
- Hypothalamic amenorrhea (e.g., Diabetes, celiac disease,
| | | | |
excessive exercise/caloric restriction, stress, lesions of
| | | | | |
hypothalamus/pituitary)
|
- Hyperprolactinemia
- Thyroid disease |
- PCOS
VIN Low-grade squamous intraepithelial lesion (LSIL)
| | | | |
,Page |2 |of |31
Not precancerous
|
HPV 6 & 11
| | | |
Adrenal Insufficiency |
- Hypofunction of adrenal gland and pituitary gland | | | | | |
- Diagnosed by low cortisol at baseline | | | | |
- Treatment includes glucocorticoid replacement
| | |
Female Pattern Hair Loss (FPHL)
| | | |
- Gradual hair thinning on crown of scalp
| | | | | |
- Occurs due to altered estrogen-to-androgen ratio
| | | | |
- Sometimes seen with discontinuation of HT | | | | |
Telogen Effluvium (TE)| |
- Sudden hair shedding | |
,Page |3 |of |31
- Patchy hair loss | |
- Occurs after a major life stressor, chronic illness, or
| | | | | | | |
medication (beta blocker, anticoagulant)
| | | |
Hair Loss Treatment
| |
Goal: Prevent progression of hair loss
| | | | |
- Minoxidil is FDA approved | | |
- Commonly used with Finasteride or Spironolactone | | | | |
Window of Vulnerability | |
Idea that women are exposed to hormone-related mood symptoms
| | | | | | | |
(e.g., PMS, PPD)
| | |
HT and Mood
| |
- Consider if VMS and mood changes | | | | |
- Only consider if in perimenopause or early postmenopausal
| | | | | | |
, Page |4 |of |31
Early Postmenopause (+1a/+1b)
| |
- Duration is 2 years | | |
- VMS likely |
Early Postmenopause (+1c)
| |
- Duration 3-6 years | |
- FSH stabilizes|
Late Postmenopause (+2)
| |
- Remaining lifespan |
- Increasing symptoms of urogenital atrophy
| | | |
Menopause and weight | |
- Increased fat in abdominal region
| | | |
- Decreased lean body mass | | |
NAMS CERTIFICATION EXAM NEWEST 2026 ACTUAL
EXAM QUESTIONS AND CORRECT DETAILED
ANSWERS (VERIFIED ANSWERS) ALL ANSWERED
{115 Q & A} ALREADY GRADED A+ (BRAND NEW!)
BRCA 1/2 Surgical Considerations
| | |
Bilateral-risk reducing breast surgery and BSO can decrease risks
| | | | | | | |
of cancer
| |
Secondary Amenorrhea differential with low FSH
| | | | |
- Pregnancy
- Hypothalamic amenorrhea (e.g., Diabetes, celiac disease,
| | | | |
excessive exercise/caloric restriction, stress, lesions of
| | | | | |
hypothalamus/pituitary)
|
- Hyperprolactinemia
- Thyroid disease |
- PCOS
VIN Low-grade squamous intraepithelial lesion (LSIL)
| | | | |
,Page |2 |of |31
Not precancerous
|
HPV 6 & 11
| | | |
Adrenal Insufficiency |
- Hypofunction of adrenal gland and pituitary gland | | | | | |
- Diagnosed by low cortisol at baseline | | | | |
- Treatment includes glucocorticoid replacement
| | |
Female Pattern Hair Loss (FPHL)
| | | |
- Gradual hair thinning on crown of scalp
| | | | | |
- Occurs due to altered estrogen-to-androgen ratio
| | | | |
- Sometimes seen with discontinuation of HT | | | | |
Telogen Effluvium (TE)| |
- Sudden hair shedding | |
,Page |3 |of |31
- Patchy hair loss | |
- Occurs after a major life stressor, chronic illness, or
| | | | | | | |
medication (beta blocker, anticoagulant)
| | | |
Hair Loss Treatment
| |
Goal: Prevent progression of hair loss
| | | | |
- Minoxidil is FDA approved | | |
- Commonly used with Finasteride or Spironolactone | | | | |
Window of Vulnerability | |
Idea that women are exposed to hormone-related mood symptoms
| | | | | | | |
(e.g., PMS, PPD)
| | |
HT and Mood
| |
- Consider if VMS and mood changes | | | | |
- Only consider if in perimenopause or early postmenopausal
| | | | | | |
, Page |4 |of |31
Early Postmenopause (+1a/+1b)
| |
- Duration is 2 years | | |
- VMS likely |
Early Postmenopause (+1c)
| |
- Duration 3-6 years | |
- FSH stabilizes|
Late Postmenopause (+2)
| |
- Remaining lifespan |
- Increasing symptoms of urogenital atrophy
| | | |
Menopause and weight | |
- Increased fat in abdominal region
| | | |
- Decreased lean body mass | | |
